Super Bowl 60: Food Brands Are in Denial as GLP-1s Come out Swinging

GLP‑1 drugs and related weight‑loss products are entering Super Bowl advertising (Novo Nordisk’s first Super Bowl buy; Ro and Hims & Hers also running spots) at the same time legacy consumption brands (beer, snacks, fast food) run traditional indulgence-driven creative. Empirical data cited include a 6% reduction in grocery spending within six months for GLP‑1 households (savory snacks down 10.1%), household penetration rising from 11% to over 16%, and a Morgan Stanley projection of a 75% reduction in alcohol consumption among GLP‑1 patients, implying meaningful secular demand risk for CPG/restaurant/alcohol companies that have yet to materially reframe brand positioning.

Analysis

Market structure: GLP-1 winners (Novo Nordisk/NVO and other pharma providers) gain durable demand and pricing power as household penetration climbed ~11%→16% in <12 months and could exceed 25% within 12–24 months; legacy consumption brands (snacks, beer, quick-serve restaurants) face 5–15% volume headwinds in high-frequency SKUs (savory snacks -10% observed) and will need to trade margin for reformulation/portioning. Competitive dynamics: incumbents with diversified portfolios (PEP) can partially offset US volume loss via international growth and beverages, but pure-play indulgence brands and low-margin CPGs have weakened pricing power and rising promotional risk. Supply/demand & cross-asset: GLP-1 supply tightening (short-term) supports biotech equities; longer term reduced commodity demand (corn, sugar, barley) could depress inputs and widen consumer staples credit spreads; watch beer/snack CDS and XLP vs. XLV correlations.

Risk assessment: Tail risks include regulatory price capping or Medicare negotiation of GLP-1s (materially compressing NVO’s margin within 12–24 months) and manufacturing/sterility recalls that temporarily choke supply and slow uptake. Timing: immediate (days) — marketing noise around Super Bowl; short-term (0–6 months) — measurable retail sell-through shifts and earnings-guide revisions; long-term (1–3 years) — secular consumption decline for targeted categories. Hidden dependencies: demand loss is income- and cohort-skewed (urban, higher-income early adopters), so premium brands and emerging markets may be insulated; catalysts: payer coverage decisions, new oral GLP-1 launches, and quarterly guides.

Trade implications: Tactical trades should overweight GLP-1 exposure and hedge US-centric CPG. Specific: accumulate 1–2% portfolio longs in NVO via 18–24 month LEAP calls (target +30–50% in 12–24 months) while hedging downside with a 15–20% stop. For PEP, reduce US-snack tilt and buy 3–6 month put spreads sized to cover 25–50% of current net exposure; consider long NVO / short PEP pair trade to isolate GLP-1 demand shock. Entry: act within 2–6 weeks to capture post-Super Bowl sentiment and ahead of Q1 guidance; exit or reweight if household penetration growth falls below +3ppt over a trailing 12 months.

Contrarian angles: Consensus underestimates incumbents’ ability to recoup through premiumization, smaller pack pricing, and international growth — downside may be concentrated and partially hedged by portfolio diversification (PEP). Historical parallels (tobacco/alcohol shifts) show category consolidation with survivors widening margins through SKU mix, suggesting overdone headline pessimism could present buyable dips in selected CPG leaders. Watch for unintended winners (functional foods, protein-focused chains) and for regulatory backlash against GLP-1 pricing that could create a volatile re-rating window for NVO.

Key Decisions for Investors

• Establish a 1–2% portfolio long in NVO via 18–24 month LEAP calls (e.g., Jan 2028 expiries) sized for a 30–50% upside target over 12–24 months; set a tactical stop-loss to trim if NVO equity falls 20% from entry or if household penetration growth slows to <+3ppt over a trailing 12 months.
• Reduce direct US-snacks/beverage exposure by 20–30% within 2 weeks—trim holdings in PEP (or XLP allocation) and purchase a 3–6 month PEP put spread sized to hedge 25–50% of remaining position (choose strikes ~5–8% OTM to limit premium).
• Implement a pair trade: long NVO (1.5% portfolio) / short PEP (1.0% portfolio) to isolate GLP-1 demand shock; rebalance after upcoming Q1 earnings or if Super Bowl-related sentiment shifts by >10% intraday.
• Buy 3–6 month volatility on CPG earnings risk: enter select long-put or strangle positions on high US-exposure names (PEP, BUD) ahead of Q1 guidance, allocating no more than 0.5–1% portfolio risk to options premium to capture potential re-rating.
• Within 30–90 days, monitor three catalysts as trade triggers: (1) FDA/Medicare pricing announcements, (2) quarterly guide revisions from PEP/BUD showing >3% downside to US consumption, and (3) new oral GLP-1 launches; if any occur, increase GLP-1 exposure and widen short CPG sizing by another 50%.